ADMA Biologics CFO Brian Lenz steps down; CEO Grossman named interim CFO

ADMA BIOLOGICS, INC.

CFO Brian Lenz transitions to consulting role effective April 1, 2024; consulting agreement through March 31, 2025.
CEO Adam Grossman appointed Interim CFO; executive search initiated for permanent replacement.
Grossman's 2024 base salary set at $800,000; awarded 557,728 RSUs and options for 870,950 shares at $5.40.
Lenz receives $334,875 cash bonus for 2023 performance (141% of corporate goals achieved).

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Lenz

Chief Financial Officer

ADMA · ADMA BIOLOGICS, INC.

Effective: 2024-04-01
Filed: February 28, 2024, 6:59 PM ET

Effective as of April 1, 2024, Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters, will transition from these positions to a consulting role with the Company (the “CFO Transition”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Lenz changed role as Chief Financial Officer at ADMA BIOLOGICS, INC..

Action: transitioned
Role: Chief Financial Officer

Exact text from the filing

Effective as of April 1, 2024, Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters, will transition from these positions to a consulting role with the Company (the “CFO Transition”).

View on SEC.gov

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-010100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.